Histamine targets myeloid-derived suppressor cells and improves the anti-tumor efficacy of PD-1/PD-L1 checkpoint blockade Hanna Grauers WiktorinMalin S. NilssonAnna Martner Original Article Open access 12 October 2018 Pages: 163 - 174
The expression of MHC class II molecules on murine breast tumors delays T-cell exhaustion, expands the T-cell repertoire, and slows tumor growth Tyler R. McCawMei LiTroy D. Randall Original Article 17 October 2018 Pages: 175 - 188
INT-HA induces M2-like macrophage differentiation of human monocytes via TLR4-miR-935 pathway Boke ZhangYan DuFeng Gao Original Article 19 October 2018 Pages: 189 - 200
Inhibitory functions of PD-L1 and PD-L2 in the regulation of anti-tumor immunity in murine tumor microenvironment Daisuke UmezuNana OkadaKoji Tamada Original Article 24 October 2018 Pages: 201 - 211
Analysis of tumor-infiltrating CD103 resident memory T-cell content in recurrent laryngeal squamous cell carcinoma Jacqueline E. MannJoshua D. SmithJ. Chad Brenner Original Article 25 October 2018 Pages: 213 - 220
Stromal interleukin-33 promotes regulatory T cell-mediated immunosuppression in head and neck squamous cell carcinoma and correlates with poor prognosis Yi-hui WenHan-qing LinWei-ping Wen Original Article 25 October 2018 Pages: 221 - 232
Development of CDX-1140, an agonist CD40 antibody for cancer immunotherapy Laura A. VitaleLawrence J. ThomasTibor Keler Original Article 31 October 2018 Pages: 233 - 245
The nature of the human T cell response to the cancer antigen 5T4 is determined by the balance of regulatory and inflammatory T cells of the same antigen-specificity: implications for vaccine design Matthieu BesneuxAlexander Greenshields-WatsonAwen Gallimore Original Article Open access 07 November 2018 Pages: 247 - 256
Hyperresponsiveness to interferon gamma exposure as a response mechanism to anti-PD-1 therapy in microsatellite instability colorectal cancer Wenli YuanDeyao DengJian Dong Original Article 07 November 2018 Pages: 257 - 268
Targeting the polarization of tumor-associated macrophages and modulating mir-155 expression might be a new approach to treat diffuse large B-cell lymphoma of the elderly Wagner A. PolesErika E. NishiGisele W. B. Colleoni Original Article 14 November 2018 Pages: 269 - 282
Upregulation of tumor PD-L1 by neoadjuvant chemoradiotherapy (neoCRT) confers improved survival in patients with lymph node metastasis of locally advanced rectal cancers Shu-Fen ChiangChih-Yang HuangK. S. Clifford Chao Original Article 17 November 2018 Pages: 283 - 296
Can benign lymphoid tissue changes in 18F-FDG PET/CT predict response to immunotherapy in metastatic melanoma? Christos SachpekidisLionel LarribèreAntonia Dimitrakopoulou-Strauss Original Article 26 November 2018 Pages: 297 - 303
Tumor-infiltrating immune cell subpopulations and programmed death ligand 1 (PD-L1) expression associated with clinicopathological and prognostic parameters in ependymoma Soo Jeong NamYoung-Hoon KimChang Ohk Sung Original Article 27 November 2018 Pages: 305 - 318
Phase 1 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell carcinoma Charlotte M. HuijtsInge M. Werterfor the Dutch WIN-O Consortium Clinical Trial Report Open access 09 November 2018 Pages: 319 - 329
A phase I clinical study of a cocktail vaccine of Wilms’ tumor 1 (WT1) HLA class I and II peptides for recurrent malignant glioma Akihiro TsuboiNaoya HashimotoHaruo Sugiyama Clinical Trial Report Open access 14 November 2018 Pages: 331 - 340